Arcus Biosciences
RCUS
139 hedge funds and large institutions have $1.03B invested in Arcus Biosciences in 2020 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 12 closing their positions.
421% more call options, than puts
Call options by funds: $3.44M | Put options by funds: $661K
392% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 12
176% more capital invested
Capital invested by funds: $375M → $1.03B (+$660M)
100% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 24
51% more funds holding
Funds holding: 92 → 139 (+47)
14.61% more ownership
Funds ownership: 58.73% → 73.34% (+15%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$49.8M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$41M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27M |
| 5 |
State Street
Boston,
Massachusetts
|
+$25.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
-$47.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$27M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$6.35M |
| 4 |
ACM
Aisling Capital Management
New York
|
-$4.63M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.84M |
RCUS Hedge Fund Activity: Q2 2020 in Review
139 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2020, worth a combined $1.03B — up 176% from $375M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new RCUS positions and 12 closed out — a net gain of 47 holders — while 48 added to existing stakes and 24 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $70.9M. The largest seller was Peter Svennilson, cutting an estimated $47.9M.
- 139 institutional investors held Arcus Biosciences (RCUS) as of Q2 2020, up from 92 in Q1 2020.
- Funds reported $1.03B of Arcus Biosciences stock for Q2 2020, up 176% quarter-over-quarter.
- 59 funds opened new Arcus Biosciences positions in Q2 2020 and 12 closed out, a net change of +47 holders.
- The largest Arcus Biosciences buyer in Q2 2020 was Fidelity Investments, an estimated $70.9M added.
- The largest Arcus Biosciences seller in Q2 2020 was Peter Svennilson, an estimated $47.9M sold.
Based on aggregated 13F filings for Q2 2020.